247 reports of this reaction
1.7% of all DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE reports
#12 most reported adverse reaction
EYE SWELLING is the #12 most commonly reported adverse reaction for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, manufactured by Thea Pharma Inc.. There are 247 FDA adverse event reports linking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE to EYE SWELLING. This represents approximately 1.7% of all 14,333 adverse event reports for this drug.
Patients taking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE who experience eye swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EYE SWELLING is a less commonly reported adverse event for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, but still significant enough to appear in the safety profile.
In addition to eye swelling, the following adverse reactions have been reported for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE:
The following drugs have also been linked to eye swelling in FDA adverse event reports:
EYE SWELLING has been reported as an adverse event in 247 FDA reports for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EYE SWELLING accounts for approximately 1.7% of all adverse event reports for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, making it a notable side effect.
If you experience eye swelling while taking DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.